Regression of cardiac valvulopathy related to ergot-derived dopamine agonists

Renzo Zanettini, Angelo Antonini, Gemma Gatto, Rosa Gentile, Silvana Tesei, Gianni Pezzoli

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Aims: In a previous echocardiographic prevalence study we reported a significant increase in the frequency of heart valve regurgitation in patients with Parkinson's disease taking the ergot-derived dopamine agonists pergolide and cabergoline versus controls. We followed-up our original cohort of patients to ascertain whether valvulopathy regressed after discontinuation of treatment and/or its incidence increased over time. Methods: Prospective follow-up of 101 patients treated with ergot-derived dopamine agonists included in the prevalence study: 53 given pergolide and 48 cabergoline (64% male; 66.4 ± 8.7 years of age, 11.5 ± 5.9 years of disease, 21.8 ± 5.9 months of follow-up); 55 stopped treatment while 46 continued. The main outcomes measures, were: echocardiographic quantification of regurgitant valve disease, abnormal leaflet, or cusp thickening and measurement of mitral valve tenting area. Results: Valve abnormalities regressed in about one third of patients with significant multivalvular and in about half of the patients with monovalvular regurgitation who withdrew; no progression was observed in remaining patients. Patients continuing ergot-derived dopamine agonists showed progression of cardiac valvulopathy: seven new cases with three to four regurgitation grade of any valve occurred during follow-up; this regarded also patients who had been on pergolide for many years. Conclusion: Owing to the persistence of risk of heart valve damage over time and the lack of its mid-term reversibility in many patients, we believe that pergolide and cabergoline should be prescribed only when therapeutic alternatives with a better risk/benefit ratio are unavailable and the patient has access to echocardiography.

Original languageEnglish
Pages (from-to)404-410
Number of pages7
JournalCardiovascular Therapeutics
Volume29
Issue number6
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Dopamine Agonists
Pergolide
Heart Valves
Cross-Sectional Studies
Mitral Valve
Parkinson Disease
Echocardiography
Therapeutics
Odds Ratio
Outcome Assessment (Health Care)
Incidence

Keywords

  • Cardiac valvulopathy regression
  • Drug discontinuation
  • Ergot-derived dopamine agonists
  • Parkinson disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2011). Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovascular Therapeutics, 29(6), 404-410. https://doi.org/10.1111/j.1755-5922.2010.00169.x

Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. / Zanettini, Renzo; Antonini, Angelo; Gatto, Gemma; Gentile, Rosa; Tesei, Silvana; Pezzoli, Gianni.

In: Cardiovascular Therapeutics, Vol. 29, No. 6, 12.2011, p. 404-410.

Research output: Contribution to journalArticle

Zanettini, R, Antonini, A, Gatto, G, Gentile, R, Tesei, S & Pezzoli, G 2011, 'Regression of cardiac valvulopathy related to ergot-derived dopamine agonists', Cardiovascular Therapeutics, vol. 29, no. 6, pp. 404-410. https://doi.org/10.1111/j.1755-5922.2010.00169.x
Zanettini, Renzo ; Antonini, Angelo ; Gatto, Gemma ; Gentile, Rosa ; Tesei, Silvana ; Pezzoli, Gianni. / Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. In: Cardiovascular Therapeutics. 2011 ; Vol. 29, No. 6. pp. 404-410.
@article{c9e87aa132ae4855b4e17260f7d118e1,
title = "Regression of cardiac valvulopathy related to ergot-derived dopamine agonists",
abstract = "Aims: In a previous echocardiographic prevalence study we reported a significant increase in the frequency of heart valve regurgitation in patients with Parkinson's disease taking the ergot-derived dopamine agonists pergolide and cabergoline versus controls. We followed-up our original cohort of patients to ascertain whether valvulopathy regressed after discontinuation of treatment and/or its incidence increased over time. Methods: Prospective follow-up of 101 patients treated with ergot-derived dopamine agonists included in the prevalence study: 53 given pergolide and 48 cabergoline (64{\%} male; 66.4 ± 8.7 years of age, 11.5 ± 5.9 years of disease, 21.8 ± 5.9 months of follow-up); 55 stopped treatment while 46 continued. The main outcomes measures, were: echocardiographic quantification of regurgitant valve disease, abnormal leaflet, or cusp thickening and measurement of mitral valve tenting area. Results: Valve abnormalities regressed in about one third of patients with significant multivalvular and in about half of the patients with monovalvular regurgitation who withdrew; no progression was observed in remaining patients. Patients continuing ergot-derived dopamine agonists showed progression of cardiac valvulopathy: seven new cases with three to four regurgitation grade of any valve occurred during follow-up; this regarded also patients who had been on pergolide for many years. Conclusion: Owing to the persistence of risk of heart valve damage over time and the lack of its mid-term reversibility in many patients, we believe that pergolide and cabergoline should be prescribed only when therapeutic alternatives with a better risk/benefit ratio are unavailable and the patient has access to echocardiography.",
keywords = "Cardiac valvulopathy regression, Drug discontinuation, Ergot-derived dopamine agonists, Parkinson disease",
author = "Renzo Zanettini and Angelo Antonini and Gemma Gatto and Rosa Gentile and Silvana Tesei and Gianni Pezzoli",
year = "2011",
month = "12",
doi = "10.1111/j.1755-5922.2010.00169.x",
language = "English",
volume = "29",
pages = "404--410",
journal = "Cardiovascular Therapeutics",
issn = "1755-5914",
publisher = "Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Regression of cardiac valvulopathy related to ergot-derived dopamine agonists

AU - Zanettini, Renzo

AU - Antonini, Angelo

AU - Gatto, Gemma

AU - Gentile, Rosa

AU - Tesei, Silvana

AU - Pezzoli, Gianni

PY - 2011/12

Y1 - 2011/12

N2 - Aims: In a previous echocardiographic prevalence study we reported a significant increase in the frequency of heart valve regurgitation in patients with Parkinson's disease taking the ergot-derived dopamine agonists pergolide and cabergoline versus controls. We followed-up our original cohort of patients to ascertain whether valvulopathy regressed after discontinuation of treatment and/or its incidence increased over time. Methods: Prospective follow-up of 101 patients treated with ergot-derived dopamine agonists included in the prevalence study: 53 given pergolide and 48 cabergoline (64% male; 66.4 ± 8.7 years of age, 11.5 ± 5.9 years of disease, 21.8 ± 5.9 months of follow-up); 55 stopped treatment while 46 continued. The main outcomes measures, were: echocardiographic quantification of regurgitant valve disease, abnormal leaflet, or cusp thickening and measurement of mitral valve tenting area. Results: Valve abnormalities regressed in about one third of patients with significant multivalvular and in about half of the patients with monovalvular regurgitation who withdrew; no progression was observed in remaining patients. Patients continuing ergot-derived dopamine agonists showed progression of cardiac valvulopathy: seven new cases with three to four regurgitation grade of any valve occurred during follow-up; this regarded also patients who had been on pergolide for many years. Conclusion: Owing to the persistence of risk of heart valve damage over time and the lack of its mid-term reversibility in many patients, we believe that pergolide and cabergoline should be prescribed only when therapeutic alternatives with a better risk/benefit ratio are unavailable and the patient has access to echocardiography.

AB - Aims: In a previous echocardiographic prevalence study we reported a significant increase in the frequency of heart valve regurgitation in patients with Parkinson's disease taking the ergot-derived dopamine agonists pergolide and cabergoline versus controls. We followed-up our original cohort of patients to ascertain whether valvulopathy regressed after discontinuation of treatment and/or its incidence increased over time. Methods: Prospective follow-up of 101 patients treated with ergot-derived dopamine agonists included in the prevalence study: 53 given pergolide and 48 cabergoline (64% male; 66.4 ± 8.7 years of age, 11.5 ± 5.9 years of disease, 21.8 ± 5.9 months of follow-up); 55 stopped treatment while 46 continued. The main outcomes measures, were: echocardiographic quantification of regurgitant valve disease, abnormal leaflet, or cusp thickening and measurement of mitral valve tenting area. Results: Valve abnormalities regressed in about one third of patients with significant multivalvular and in about half of the patients with monovalvular regurgitation who withdrew; no progression was observed in remaining patients. Patients continuing ergot-derived dopamine agonists showed progression of cardiac valvulopathy: seven new cases with three to four regurgitation grade of any valve occurred during follow-up; this regarded also patients who had been on pergolide for many years. Conclusion: Owing to the persistence of risk of heart valve damage over time and the lack of its mid-term reversibility in many patients, we believe that pergolide and cabergoline should be prescribed only when therapeutic alternatives with a better risk/benefit ratio are unavailable and the patient has access to echocardiography.

KW - Cardiac valvulopathy regression

KW - Drug discontinuation

KW - Ergot-derived dopamine agonists

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=79955672955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955672955&partnerID=8YFLogxK

U2 - 10.1111/j.1755-5922.2010.00169.x

DO - 10.1111/j.1755-5922.2010.00169.x

M3 - Article

VL - 29

SP - 404

EP - 410

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 6

ER -